Author

Marius Wits

Leiden University Medical CenterORCID 0000-0003-1837-3481Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexandre DeberiD· 2 shared Francesc VenturaiD· 2 shared Gonzalo Sánchez‐DuffhuesiD· 2 shared Marie‐José GoumansiD· 2 shared Aida Llucià ValldeperasiD· 1 shared Bharath K. SampadiiD· 1 shared Carolina Pimenta-LopesiD· 1 shared Christiaan H. ArendzeniD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Alexandre DeberORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular BiologyeLifePeer-reviewedJun 17, 2025

PI3Kα inhibition blocks osteochondroprogenitor specification and the hyper-inflammatory response to prevent heterotopic ossification

José Antonio Valer, Alexandre Deber, Marius Wits…·Francesc Ventura

This study confirms that PI3K inhibition with BYL719 prevents heterotopic ossification by blocking osteochondroprogenitor specification and reducing inflammation.

DOI 10.7554/elife.91779

mouseexperimental assay

𝕏 PostBluesky

Molecular BiologybioRxivPreprintJan 21, 2025

Multi-omics reveals global signaling rewiring and identifies Activin A-induced dysregulation of FOS/Activator Protein 1 as a novel target in Fibrodysplasia ossificans progressiva

Marius Wits, Nerea Gomez-Suarez, Alexandre Deber…·Gonzalo Sánchez‐Duffhues

The paper uses multi-omics analyses to identify signaling dysregulation in FOP, highlighting AP-1 as a novel therapeutic target.

DOI 10.1101/2025.01.21.634061

humanproteomics

𝕏 PostBluesky